Omada Health, Inc.(OMDA)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #934 of 2,962 stocksTOP 50%
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
OMDA Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for Omada Health, Inc. (OMDA), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores OMDA at 59.4/100 on a 32-signal composite quality model, placing it at rank #934 of 2,962 stocks — the top half of the AI-ranked universe. OMDA scores in the top quartile across earnings quality (97.4), revenue growth (83.5), institutional flow (80.4). Areas of concern include revenue scale (30.0), which score below median versus the broader universe. Shareholder dilution risk is elevated at 24.8/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Omada Health, Inc. reports quarterly revenue of $87.8M, net income of $5.3M, free cash flow of $3.9M. Top institutional holders of OMDA by reported 13-F value include Revelation Capital Management, Divisadero Street Capital Management, AMERICAN CENTURY COMPANIES, based on the most recent SEC filings. OMDA trades on the Nasdaq exchange and files with the SEC under CIK 1611115. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate OMDA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Omada Health, Inc. directly from SEC EDGAR. Omada Health, Inc.'s 13F Pro composite quality score has ranged between 32 and 59 since 2026, currently 59.4 — an improving long-term trajectory across 40 quarterly and live scoring snapshots.
Revenue
Q2 2026
$87.8M
Net Income
Q2 2026
$5.3M
Free Cash Flow
Q2 2026
$3.9M
ROIC
Q2 2026
5.6%
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
+53.2% YoYNet Income
+72.9% YoYOperating Income
+72.6% YoYEPS (Diluted)
+59.9% YoYTotal Assets
+102.4% YoYTotal Debt
-100.0% YoYOp. Cash Flow
+153.4% YoYFree Cash Flow
+148.7% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Revenue | $260.2M +53.2% | $169.8M +38.3% | $122.8M | — |
| Net Income | $-12.8M +72.9% | $-47.1M +30.2% | $-67.5M | — |
| Operating Income | $-12.0M +72.6% | $-43.7M +33.9% | $-66.0M | — |
| EPS (Diluted) | $-0.35 +59.9% | $-0.87 +35.8% | $-1.36 | — |
| Total Assets | $305.4M +102.4% | $150.9M | — | — |
| Total Debt | $0.00 -100.0% | $29.8M | — | — |
| Operating Cash Flow | $18.3M +153.4% | $-34.2M +31.3% | $-49.7M | — |
| Free Cash Flow | $16.9M +148.7% | $-34.8M +30.7% | $-50.2M | — |
Get alerted when OMDA's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Omada Health, Inc. including:
Top Institutional Holders of OMDA
Revelation Capital Management, LLC
$106.6M4,858,034 shDivisadero Street Capital Management, LP
$83.4M3,799,695 shAMERICAN CENTURY COMPANIES INC
$80.7M3,678,676 shCIGNA INVESTMENTS INC /NEW
$75.6M3,444,629 shMORGAN STANLEY
$61.5M2,800,887 shFMR LLC
$60.9M2,775,102 shNVP Associates, LLC
$55.6M2,531,000 shBlackRock, Inc.
$48.8M2,222,074 shVANGUARD CAPITAL MANAGEMENT LLC
$42.3M1,926,594 shMILLENNIUM MANAGEMENT LLC
$37.8M1,724,057 sh
| Fund | Value | Shares |
|---|---|---|
| Revelation Capital Management, LLC | $106.6M | 4,858,034 |
| Divisadero Street Capital Management, LP | $83.4M | 3,799,695 |
| AMERICAN CENTURY COMPANIES INC | $80.7M | 3,678,676 |
| CIGNA INVESTMENTS INC /NEW | $75.6M | 3,444,629 |
| MORGAN STANLEY | $61.5M | 2,800,887 |
| FMR LLC | $60.9M | 2,775,102 |
| NVP Associates, LLC | $55.6M | 2,531,000 |
| BlackRock, Inc. | $48.8M | 2,222,074 |
| VANGUARD CAPITAL MANAGEMENT LLC | $42.3M | 1,926,594 |
| MILLENNIUM MANAGEMENT LLC | $37.8M | 1,724,057 |
Companies Similar to OMDA
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
iRhythm Holdings, Inc.
Xeris Biopharma Holdings, Inc.
Tarsus Pharmaceuticals, Inc.
AtriCure, Inc.
Axogen, Inc.
Travere Therapeutics, Inc.
MiniMed Group, Inc.
BillionToOne, Inc.
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put OMDA on your watchlist
Track score changes the day Omada Health, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is OMDA a good stock to buy?
13F Pro's AI-powered analysis of Omada Health, Inc. (OMDA) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for OMDA are available on the OMDA stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. OMDA is classified as a small company.
Which hedge funds own OMDA?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling OMDA. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Omada Health, Inc.'s investment landscape.